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IMPORTANCE Risk factors for abdominal aortic aneurysm (AAA) are largely unknown,which has
hampered thedevelopment of nonsurgical treatments to alter the natural history of disease.
OBJECTIVE To investigate the association between lipid-associated single-nucleotide
polymorphisms (SNPs) and AAA risk.
DESIGN, SETTING, AND PARTICIPANTS Genetic risk scores, composed of lipid trait–associated
SNPs, were constructed and tested for their association with AAA using conventional
(inverse-variance weighted) mendelian randomization (MR) and data from international AAA
genome-wide association studies. Sensitivity analyses to account for potential genetic
pleiotropy includedMR-Egger and weightedmedianMR, andmultivariable MRmethod was
used to test the independent association of lipids with AAA risk. The association between
AAA and SNPs in loci that can act as proxies for drug targets was also assessed. Data
collection took place between January 9, 2015, and January 4, 2016. Data analysis was
conducted between January 4, 2015, and December 31, 2016.
EXPOSURES Genetic elevation of low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C), and triglycerides (TG).
MAIN OUTCOMES ANDMEASURES The association between genetic risk scores of
lipid-associated SNPs and AAA risk, as well as the association between SNPs in lipid drug
targets (HMGCR, CETP, and PCSK9) and AAA risk.
RESULTS Up to 4914 cases and 48002 controls were included in our analysis. A 1-SD genetic
elevation of LDL-C was associated with increased AAA risk (odds ratio [OR], 1.66; 95% CI,
1.41-1.96; P = 1.1 × 10−9). For HDL-C, a 1-SD increase was associated with reduced AAA risk
(OR, 0.67; 95% CI, 0.55-0.82; P = 8.3 × 10−5), whereas a 1-SD increase in triglycerides was
associated with increased AAA risk (OR, 1.69; 95% CI, 1.38-2.07; P = 5.2 × 10−7). In
multivariable MR analysis and bothMR-Egger and weightedmedianMRmethods, the
association of each lipid fraction with AAA risk remained largely unchanged. The
LDL-C–reducing allele of rs12916 inHMGCRwas associated with AAA risk (OR, 0.93; 95% CI,
0.89-0.98; P = .009). The HDL-C–raising allele of rs3764261 in CETPwas associated with
lower AAA risk (OR, 0.89; 95% CI, 0.85-0.94; P = 3.7 × 10−7). Finally, the LDL-C–lowering
allele of rs11206510 in PCSK9was weakly associated with a lower AAA risk (OR, 0.94; 95% CI,
0.88-1.00; P = .04), but a second independent LDL-C–lowering variant in PCSK9 (rs2479409)
was not associated with AAA risk (OR, 0.97; 95% CI, 0.92-1.02; P = .28).
CONCLUSIONS AND RELEVANCE TheMR analyses in this study lend support to the hypothesis
that lipids play an important role in the etiology of AAA. Analyses of individual genetic
variants used as proxies for drug targets support LDL-C lowering as a potential effective
treatment strategy for preventing andmanaging AAA.
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A bdominal aortic aneurysm (AAA) is an important car-diovascular disease (CVD) resulting in approximately4500 deaths fromAAA rupture per year in the United
States.1 Approximately45000operations are carriedout each
year to prevent rupture, resulting in 1400 deaths.1 Screening
for AAA reduces the burden of rupture,2 and therefore many
countriesnowoffer such screening to at-risk groups.3,4 TheUS
Preventive Services Task Force recommends screening men
aged 65 to 75 years with a history of smoking, and the Ameri-
can Heart Association guidelines suggest surgical repair is
needed when the AAA reaches 5.5 cm in diameter.
Abdominal aortic aneurysmshares risk factorswithocclu-
sive atherosclerotic disease, but the magnitude and direction
of this association is not always consistent. A growing body
of evidence suggests considerable heterogeneity of risk factor
associations among different forms of CVDs.5-7 For example,
the risk of smoking for AAA is at least 2-fold greater than that
for coronary heart disease (CHD),7whereas type 2diabetes ap-
pears to be protective for AAA but is amajor risk factor for oc-
clusivevasculardisease.6This example suggests thatAAAmay
have somedistinct causal pathways, and understanding these
pathways is important for setting public health policies aimed
at reducing the risk posed by AAA and its complications.
Genome-wide association studies (GWASs) of AAA have
identified robust associationsof loci thathavepreviouslybeen
found for CHD (9p21),8DAB2IP (Entrez Gene 153090),9 LDLR
(Entrez Gene 3949),10 SORT1 (Entrez Gene 6272),11 and IL6R
(Entrez Gene 3570)12 as well as a number of variants that do
notappear tobeassociatedwithotherCVDs (LRP1 [EntrezGene
4035],13SMYD2 [EntrezGene56960],ERG [EntrezGene2078],
MMP9 [Entrez Gene 4318], and LINC00540 [Entrez Gene
100506622]14). Again, these findings lend support to the
hypothesis that AAA and CHD have overlapping pathophysi-
ology, but the association with AAA and not with other CVDs
suggests that discrete etiological pathways may well exist
between these vascular diseases.
The roleof low-density lipoproteincholesterol (LDL-C) lev-
els in CHD iswell defined, andLDL-C lowering therapies are of
clear benefit in reducing CHD risk.15 Genetic studies appear to
support a causal role for hypertriglyceridemia in CHD,16-18 but
geneticandclinicalstudieshavecastdoubtonthestatusofhigh-
density lipoprotein cholesterol (HDL-C) as a causal factor in
CHD.16,18-21 In AAA,meta-analyses of observational studies do
showa consistent inverse association ofHDL-CwithAAA risk,
but the associationwithLDL-C is less clear.22,23 It is important,
however, to recognize that the studies included in thesemeta-
analysesweresmall case-control studies,manyofwhichdidnot
adjust for statinuse. There is apaucity of anydata reporting an
associationbetweentriglycerides (TG)andAAAriskorprogres-
sion. From a clinical point of view, it is important to under-
stand the role of lipids in AAA, especially considering the ex-
cess cardiovascular risks inpatientswithAAA24 and the recent
publicationsshowinglowprevalenceof loweringlevelsofLDL-C
inpatientswithAAA.25,26 Previous genetic association studies
havepointedtoapotential roleof lipids inAAApathology,10,11,27
but this current study uses a larger panel of single-nucleotide
polymorphisms (SNPs), a considerably larger sample, andmore
advancedmethods.
Mendelian randomization (MR) is an approach that uses
the unique properties of genotype to investigate causal
associations.28 Specifically, genotype is randomly allocated at
conception (owing to Mendel’s second law, a feature that is
exploited tominimize confounding) and is not affected by re-
verse causation. Although MR has traditionally been used to
explorecausalassociationsbetweencirculatingbiomarkersand
disease phenotypes, it has an extension that uses genotype
tovalidatedrug targets. In this approach, variants in genes en-
coding potential drug targets are used as instruments to ex-
plore the utility of targeting this pathway in specific disease
states.29,30 Amajor challenge inMR studies of complex traits
such as lipid fractions is genetic pleiotropy,whereby SNPs in-
fluence circulating concentrations ofmultiple lipid fractions.
This so-called pleiotropymay reflect an association of an SNP
(ormultiple SNPs in combination)withmultiplediscretepath-
ways that may have differing associations with AAA, leading
to a potentially biased estimate from MR. Recent develop-
ments in the technique, such asmultivariableMR,16weighted
medianMR,31 andMR-Egger,32havebeenusedtoaddress these
issues, but pleiotropy still poses a challenge.
In this study, conventional inverse-varianceweightedMR,
multivariable MR, weighted median MR, and MR-Egger
approaches were used to investigate the role of lipids in the
etiology of AAA.
Methods
From January 9, 2015, to December 21, 2016, we investigated
the associationof genetic risk scores (GRS) for lipid traitswith
AAA reported in up to 4914 cases and 48002 controls across
5 internationalAAAGWASs14 that tookplace in theUnitedKing-
dom and Australia,13,14 New Zealand,13,14 the United States,14
theNetherlands,andIceland.9TheGRSwerecomposedofSNPs
that are robustly associated with serum lipids in the Global
Lipids Genetics Consortium meta-GWAS of circulating lipid
levels.33Datacollection for this study tookplacebetweenJanu-
ary 9, 2015, and January 4, 2016. Data analysis was con-
ducted between January 4, 2015, and December 31, 2016.
Study Populations
We used summary SNP-AAA association statistics from the 5
publishedGWASsofAAA.Detaileddescriptionsof theseGWAS
Key Points
Question What is the association between genetically elevated
lipid levels and the risk for abdominal aortic aneurysm?
Findings In this meta-analysis of up to 4914 cases and 48002
controls in 5 genome-wide association studies, genetic elevation
of low-density lipoprotein cholesterol and triglyceride levels were
associated with an elevated risk of abdominal aortic aneurysm and
high-density lipoprotein cholesterol level was associated with a
lower risk of abdominal aortic aneurysm.
Meaning Patients with abdominal aortic aneurysm have a high
burden of genetically determined dyslipidemia; targeting lipids in
this high-risk groupmay improve longer-term outcomes.
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analysesareprovided in theeAppendix in theSupplementand
previous publications.9,13,14 We supplemented the study of
single variants in genes encoding lipid drug targets with data
derived from the Secondary Manifestations of Arterial Dis-
eases (SMART) study. TheTable includes thenumber of cases
and controls in each study. Descriptions of study cohorts and
demographic details are presented in the eAppendix in the
Supplement andpreviouspublications.9,13,14 In all studies, the
case definition of AAA was an infrarenal aortic diameter of 3
cmormore by ultrasound or computed tomographic imaging
or previous AAA rupture or repair. Details of the association
tests andquality control used ineach studyare included in the
eAppendix in the Supplement and apublishedmeta-GWAS.14
Selection of SNPs
WeidentifiedSNPsassociatedwith lipids in theGlobalLipidGe-
neticsConsortium33usingtheSNPselectioncriteriabyDoetal.16
Briefly, SNPs in association with at least 1 of the 3 lipid traits
(LDL-C, HDL-C, or TG concentrations) at a genome-wide sig-
nificance level (P < 5 × 10−8) were selected. In Do et al16 at loci
withmultiple associated SNPs, single SNPs with the strongest
effect estimates were selected, and more than 1 SNP was se-
lected only if there was evidence of minimal linkage disequi-
librium (r2 < 0.05). Datawere available for the 180 of 185 SNPs
(eTable 1 in the Supplement) described in Do et al.16
Data Analysis
We first harmonized SNPs across the data sets (Global Lipids
Genetics Consortium and Aneurysm Consortium) by merging
SNPs on the reference SNP cluster identification or rs number.
Then,weensuredthateffectallelesweredenotedtobethesame
inbothdata sets anddouble-checked the informationby inves-
tigatingeffect-allele frequencies.Weorientedall variants toen-
sure that the effect allele was positively associated with each
lipid trait (eg, in the MR of LDL-C, all β coefficients for LDL-C
were >0). This orientation resulted in a data set in which each
SNP was a unique row and there were separate columns for β
and SEs for each lipid trait and the log odds ratio (OR) and cor-
responding SE for AAA (eTable 1 in the Supplement).
Conventional MR
We conducted a conventional 2-sampleMR analysis to deter-
mine the associationbetweena 1-SDgenetically elevated lipid
concentration and AAA risk. For this analysis, we used the
inverse-variance weighted MR method in which the SNP as-
sociation estimates for the outcome (β for AAA) are regressed
on the SNP association estimates for each lipid (β for LDL-C,
β for HDL-C, and β for TG) individually in turn. The regres-
sion was weighted by the inverse variances of the estimated
associationsof theSNPswith theoutcomeandthenwas forced
to pass through the origin.
MultivariableMR
To gauge some insight into potential “independent” associa-
tionsof the lipidswithAAArisk,weused themultivariableMR
method. In this approach, a single regressionmodelwith out-
come variable (β for AAA) was fitted for the predictor vari-
ables (β for LDL-C, β for HDL-C, and β for TG). Themodel was
implemented, as described previously,34 as a multilinear re-
gression of SNP association estimates weighted by the
inverse variances of the estimated associations of SNPs with
the outcome and forced to pass through the origin.
MR-Egger
Weused theMR-Egger32method that tests for the presence of,
and provides anMR estimate that is adjusted for, unmeasured
net pleiotropy. The method involves conducting an uncon-
strained linear regression of the SNP association estimates
for theoutcomeon theSNPassociationestimates for theexpo-
sure weighted by the inverse variance of the estimated asso-
ciation of SNPwith outcome. InMR-Egger, any net pleiotropy
manifests in the intercept.Under theassumption thatpleiotro-
picassociationsare independentof theassociationsof theSNPs
with the exposure, the regression slope coefficient should
represent an unbiasedMR association estimate.
WeightedMedianMR
As a further sensitivity analysis, we performed the weighted
median MR method.31 Whereas the conventional inverse-
varianceweightedmethod calculates aweightedmean of the
SNP-specific causal association estimates, the weighted me-
dian method calculates a weighted version of the median of
the SNP-specific causal association estimates. Because the
medianof adistribution is not affectedbyextremevalues, the
weightedmedianmethod is less sensitive to individual pleio-
tropicSNPs.Theweightedmedianestimate isunbiased in large
samples if at least 50%of theweights fromSNPs are valid (eg,
not pleiotropic).
Table. Summary of Abdominal Aortic AneurysmGenome-Wide Association Studies
GWAS Data Set Cases, No. Controls, No. Notes
Aneurysm Consortium (United Kingdom and Australia)a 1866 5435 WTCCC Common Control Group, nonscreened
Vascular Genetics Study (New Zealand)a 1005 996 Screened AAA-negative controls (<2.5 cm); 80% AAA >5 cm
GWAS (United States)a 724 1870 Cases identified in electronic health records, nonscreened
deCODE Genetics (Iceland)a 479 36 910 Nonscreened population
GWAS (the Netherlands)a 840 2791 Nonscreened population
SMARTb 631 6342 AAA-negative controls with arterial diseasec
Abbreviations: AAA, abdominal aortic aneurysm; GWAS, genome-wide
association study; NA, not applicable; SMART, Secondary Manifestations of
Arterial Diseases study; WTCCC, Wellcome Trust Case Control Consortium.
a This cohort was used in themendelian randomization of lipids (genetic risk
score) analysis.
b This cohort was used in themendelian randomization of drug targets analysis.
c Reflecting a single variant study only.
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SNPs in Drug Target Analysis
To our knowledge, there have been no large-scale random-
ized trials of lipid-lowering treatments in patients with AAA,
and observational studies have often been small and retro-
spective andyieldedheterogeneous results.Weexamined the
association of rs12916 inHMGCR (a genetic proxy for statins;
Entrez Gene 3156), rs3764261 in CETP (a proxy for CETP
inhibitors; Entrez Gene 1071), as well as rs2479409 and
rs11206510 in PCSK9 (a proxy for PCSK9 inhibitors; Entrez
Gene 255738) with AAA to identify the potential utility of
pharmacological modification of these drug targets in AAA.
Statistical Calculations
The MR analyses for blood lipids were performed using the
“MendelianRandomization” command in R, version 3.3.3
(R Foundation for Statistical Computing),35 and 2-tailed
P valueswere derived from instrumental variable estimators.
Given that there was only one outcome under investigation
(AAA) and the lipids traits were correlated with one another,
we used 2-tailed P < .05 to denote evidence against the null
hypothesis (ie, P < .05 provided evidence in favor of an
association between the exposure and outcome).
Results
Thenumbersofcasesandcontrols foreachof the5AAAGWASs
are shown in the Table. Up to 4914 cases and 48002 controls
were included in our analysis. The complete list of SNPs ana-
lyzed in this study, together with information on the associa-
tion statistics for AAA, and for LDL-C, HDL-C, and TG levels,
is included in eTable 1 in the Supplement.
Conventional Inverse-VarianceWeightedMR:
Association of GRSWith AAA
Summarystatistics for 180 lipid-associatedSNPswereavailable
for analysis. As previously reported,11,14 the LDL-C–lowering
alleles of rs6511720 in LDLR (OR per allele, 0.75; 95%CI, 0.67-
0.83;P = 5.2 × 10−12)andrs646776inSORT1 (ORperallele,0.88;
95% CI, 0.82-0.94; P = 3.9 × 10−8) were strongly associated
withAAA.NootherSNPfromthe180 lipid-associatedSNPswas
individually associated with AAA at conventional levels of
genome-wide significance (P < 5.0 × 10−8). Twenty-fiveof 180
SNPs (13.8%) were nominally associated with AAA (P < .05;
eTable 2 in the Supplement)with 9 such associations (95%CI,
4-15) being expected by chance alone.
Weconductedconventional inverse-varianceweightedMR
analysesusingGRS for LDL-C (75 SNPs),HDL-C (84SNPs), and
TG levels (50 SNPs) to assess the associations with AAA
(Figure 1). TheLDL-GRSwas strongly associatedwithAAArisk
(OR per SD higher level for LDL-C, 1.66; 95% CI, 1.41-1.96;
P = 1.1 × 10−9).A1-SDhigherHDL-C level instrumentedthrough
the HDL-C GRS was associated with a reduced AAA risk
(OR, 0.67; 95% CI, 0.55-0.82; P = 8.3 × 10−5). In addition, the
TG-GRS was associated with higher AAA risk (OR per 1-SD
higher TG level, 1.69; 95% CI, 1.38-2.07; P = 5.2 × 10−7).
MultivariableMR,MR-Egger,
andWeightedMedianMRApproaches
It ispossible to removeSNPswithpleiotropicassociations from
the GRS, but this removal diminishes the strength of the in-
strumental variable36 and can introduce bias.37 Therefore,we
adopted themultivariableMRmethoddescribed byDo et al16
andmodified byBurgess andThompson34 to gain insight into
thepotential independent associationsof these lipidGRSwith
AAA risk. To account for any net unbalanced pleiotropy, we
used theMR-Eggermethod. To reduce the influence of outly-
ing (possiblypleiotropic) variants on the analysis,weused the
weighted median MR method. None of these sensitivity MR
analyses resulted in a material change to either the magni-
tude or significance of the estimates (Figure 1). The point es-
timates for concentrations of LDL-C and HDL-C remained
largely unaltered, whereas for TG the point estimate dimin-
ished for the multivariable MR method; however, on the
MR-Egger and weighted median MR methods, TG level
remained convincingly associated with AAA.
Figure 1. Association of Lipid Genetic Risk ScoresWith Abdominal Aortic Aneurysm (AAA) Risk
P Value
Favors Higher
Concentration
of Lipid
Favors Lower
Concentration
of Lipid
3.01.00.2
OR (95% CI)
MR Method
LDL-C
OR of AAA per SD
Higher Lipid Level
(95% CI)
1.1 × 10–9Inverse-variance weighted 1.66 (1.41-1.96)
8.4 × 10–7MR-Egger 1.94 (1.49-2.52)
1.3 × 10–5Weighted median 1.68 (1.33-2.12)
1.8 × 10–8Multivariable 1.56 (1.34-1.82)
HDL-C
8.3 × 10–5Inverse-variance weighted 0.67 (0.55-0.82)
6.0 × 10–4MR-Egger 0.56 (0.41-0.78)
.02Weighted median 0.74 (0.58-0.95)
2.0 × 10–3Multivariable 0.73 (0.60-0.89)
TG
5.2 × 10–7Inverse-variance weighted 1.69 (1.38-2.07)
2.0 × 10–3MR-Egger 1.71 (1.21-2.40)
9.8 × 10–5Weighted median 1.68 (1.29-2.19)
.10Multivariable 1.21 (0.96-1.51)
The 4 different mendelian
randomization (MR) methods used to
determine this association were
conventional inverse weightedMR,
MR-Egger, weightedmedianMR, and
multivariable MR. LDL-C indicates
low-density lipoprotein cholesterol;
HDL-C, high-density lipoprotein
cholesterol; OR, odds ratio; and
TG, triglycerides (TG).
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Association of SNPsWith Lipid Drug Targets
We selected rs12916 inHMGCR, rs3764261 in CETP, as well as
rs2479409andrs11206510 inPCSK9as thereare licenseddrugs
that target pathways associated with these genes.
The LDL-C–lowering allele of rs12916 (to proxy statin use)
was associatedwith a lowerAAA risk inmeta-analysis (ORper
LDL-C–lowering allele, 0.93; 95% CI, 0.89-0.98; P = .009)
(Figure 2).
The PCSK9 inhibitors are a novel class of drugs used to
targetLDL-C.Todate, inCHD,genetic andclinical studieshave
had concordant results.33,38 We examined 2 independent
SNPs in PCSK9 (rs2479409 and rs11206510; linkage disequi-
librium r2 = 0.07) that were used as proxies for PCSK9 inhibi-
tion in a large-scale MR analysis39 and have strong, indepen-
dent associations with both LDL-C levels and CHD. The
LDL-C–lowering allele of rs2479409 was not associated
with AAA risk (OR, 0.97; 95% CI, 0.92-1.02; P = .28). The
LDL-C–lowering allele of rs11206510 in PCSK9 was weakly
associatedwithAAArisk (OR,0.94;95%CI,0.88-1.00;P = .04)
(Figure 2).
We used rs3764261 as a proxy for CETP inhibition.
Although the allele increases HDL-C levels, it is also associ-
ated with lower circulating concentrations of TG and LDL-C;
thus, rs3764261 cannot be considered as an instrument for
HDL-C in isolation but can be used to gauge insight into the
potential associations with CETP inhibition.30 This HDL-
raisingCETP SNPwas associatedwith lower AAA risk (OR per
HDL-C–raising allele, 0.89; 95%CI, 0.85-0.94;P = 3.7 × 10−7).
Discussion
Understanding the relevanceof lipid fractions in thedevelop-
ment of AAA has important implications from both etiologi-
cal and translational standpoints. In this study, we used MR
to provide robust evidence that the major lipid fractions—
LDL-C,HDL-C, andTG—are likely toplay important roles in the
etiology of AAA. A similar genetic approach has been used
previously,27 but thispresent studyhasexpandedon this tech-
niqueby includingmanymore individuals andmoreSNPsand
by using more recent developments in MR, which collec-
tively increase statistical power and strengthen thevalidity of
the association estimates reported here.
Disentangling the rolesof correlatedbiomarkers indisease
etiologycontinues tobeananalytical challenge; to this end,we
used recently developed techniques for the multivariable MR
method.16 Interestingly, there appear to be independent asso-
ciations between genetically instrumented levels of LDL-C,
HDL-C, andTGandAAArisk.This finding is in contrast to find-
ings instudiesofCHDinwhichasimilarapproachfoundweaker
associations between HDL-C genetic variants and CHD (after
shared pathways with LDL-C and TG and pleiotropy had been
taken into account16,18,19,36) or aortic stenosis in which only
LDL-C appeared to play a causal role.40 This finding highlights
the complexity of lipid pathways across the diverse biology of
CVD and suggests that results from studies focused solely on
CHD(whichcanbedefinedvariably) cannotalwaysbeextrapo-
lated to other vascular diseases such as AAA.
Although it has been possible to investigate for pleiotro-
picassociationsofgeneticvariantsusedcollectively in the lipid
GRS employed in the MR analyses we conducted, it is not so
straightforward as to disentangle the phenotypic overlap
wherebymany patients with AAA also harbor atherosclerotic
disease inothervascular beds.Therefore, it is tempting to sug-
gest a causal role for lipids specifically in AAA pathogenesis,
but these genetic analyses do not provide definitive evi-
dence. The data do suggest, however, that the burden of ge-
netically influenceddyslipidemia inpatientswithAAA is con-
siderable,andbyextrapolation, theseMRanalyses lendsupport
to the lipidsplayingan important role inAAAetiologyand thus
targeting lipids through pharmacological modification in pa-
tientswith small AAAsmaywell be justified. This point is par-
ticularly pertinent given the recent reports of low prevalence
of controlofLDL-Cconcentrations inpatientswithAAAinboth
theUnitedStatesandtheUnitedKingdom.25,26 Inaddition, this
groupofpatientsshouldbeconsidered intrialsevaluatingnovel
treatments of lipid-lowering medications, such as CETP or
PCSK9 inhibitors.
The use of genetic data to inform drug trials and/or drug
repurposing representsan important translational facetofdata
derivedby largegenome-wideconsortia.41,42 Inaddition to the
GRS for LDL-C, HDL-C, and TG, we looked at 4 loci that serve
Figure 2. Association of Single-Nucleotide Polymorphisms (SNPs) in Genes Encoding Drug TargetsWith Abdominal Aortic Aneurysm (AAA) Risk
Favors
LDL-C
Lowering
Favors
LDL-C
Raising
2.01.00.8
OR (95% CI)
SNP No. of Cases No. of Controls
HMGCR gene (LDL-C−lowering effect allele)
OR of AAA per
Allele (95% CI)
rs12916 4914 48 002 0.93 (0.89-0.98)
PCSK9 gene (LDL-C−lowering effect allele)
rs2479409 4914 48 002 0.97 (0.92-1.02)
rs11206510 4914 48 002 0.94 (0.88-1.00)
CETP gene (HDL-C−raising and LDL-C lowering effect allele)
rs3764261 5545 54 344 0.89 (0.85-0.94)
SNPs were proxies for lipid drug targets. Analysis of CETP gene included additional cases and controls from the Secondary Manifestations of Arterial Diseases
(SMART) study. LDL-C indicates low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; and OR, odds ratio.
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as proxies for cardiovascular drug targets that have not been
subjected toclinical trials inpatientswithAAA.Both theLDL-C
GRS and a genetic proxy for statin therapy (SNPs in HMGCR)
were associatedwith AAA. Previous investigations on the as-
sociations of concentrations of LDL-C with AAA have used
cross-sectionaldatasetswithvarying findings,andresultshave
been hampered by concurrent LDL-C–lowering therapies.43
Indeed, there has been a suggestion that statin use may in-
crease AAA risk.44 The collective results from this study sug-
gest that LDL-Cplays an important role in theetiologyofAAA,
whichmay explain the excess burden of CVD in patients with
AAA.24 These data also support a view that patients found by
screening to have AAA should be prescribed statins to reduce
their CVD risk, although whether this will affect the progres-
sion of AAA cannot be answered in this study.
A recent phase 3 clinical trial showed that PCSK9 inhibi-
tors have beneficial effects onCVDoutcomes.38 Although the
association we found between PCSK9 variants and AAA was
weak, if PSCK9 inhibitors do prove to be a safe and cost-
effectivemeans of lowering LDL-C levels, then consideration
shouldbegiven toevaluating thesedrugs inpatientswithAAA.
Asnoted,agenetically instrumentedhigherHDL-Clevelwas
identified to be associated with a reduction in AAA risk. Vari-
ants inCETPhave a rangeof results similar to pharmacological
inhibition of CETP,30 including lowering of LDL-C and raising
ofHDL-C levels.A trial ofCETP inhibition showedmodestben-
efit inpatients followingmyocardial infarction,45 and thereare
data to support its beneficial effects on vascular remodeling46
that could have relevance in AAAmanagement. Evaluation of
CETP inhibition in patients with AAA may therefore be war-
ranted.Althoughwecannotspecificallydeterminewhether the
association between CETP polymorphisms and AAA is via
HDL-C, LDL-C, or TG (or indeed all, as suggested by our GRS of
lipid traits), we believe our results suggest that CETP inhibi-
tion could play a role in themanagement of AAA.
Thefindings regardingTGvariantsalsohavepotential clini-
cal implications for thedevelopmentofnovel treatmentsaimed
at TG levels. They suggest that patients with AAA may ben-
efit from loweringTG levels.Asnovel therapies suchasAPOC3
inhibitors progress fromphase 2 studies to larger-scale phase
3 studies of CVDprevention, thenpatientswithAAA could be
an important CVD subphenotype in whom treatment should
be evaluated.
Our study used MR, a genetic approach that has impor-
tant assumptions. The SNPs used in the genetic instruments
for each lipid trait were identified from recent GWASs that
placed stringent thresholds onSNPdiscovery.As such, the ge-
netic instruments are very unlikely to suffer from weak in-
strument bias; in any case, because the MR analyses used
nonoverlapping data sets, such bias would tend to dilute the
estimates derived fromMR analyses.47 In addition, we made
the assumption that the genetic instruments are not influ-
enced by confounding and that they only associate with AAA
through the exposure of interest (ie, the genetic instruments
are not affected by unbalanced horizontal pleiotropy, as pic-
torially illustrated in Figure 1 ofWhite et al18 and expanded in
Holmesetal37).Theseassumptionscannotbe testedwithcom-
plete certainty. However, causal estimates obtained from a
rangeof sensitivityanalyses, eachmakingdifferentandweaker
assumptions, all gave similar results. Nonetheless, residual
pleiotropy could still influence our findings.
Limitations
The limitations of this study should be considered. First, we
did not have data sets to evaluate AAA progression. Second,
owing to limited availability of covariate data, we were
unable to examine the influence of concurrent lipid-lowering
therapy on the estimates derived from the GRS for blood lipid
traits and AAA risk. Third, our analyses used summary-level
data as described elsewhere.16,48 Use of summary-level data
can hamper more refined analyses (eg, subgroup analyses by
sex or age), but one of its main strengths is it facilitates
2-sample MR analyses of the type reported here. This greatly
strengthens the power of the study, which enables the con-
duct of sensitivity analyses (such as MR-Egger and weighted
median MR methods) and the investigation of certain instru-
mental variable assumptions such as the absence of genetic
pleiotropy. Finally, although we attempted to control for
pleiotropy in the analyses, we believe pleiotropy still repre-
sents a major challenge to deciphering the roles of specific
lipid-based pathways.
Conclusions
Using contemporaryMRapproaches,we founddata that lend
support to the hypothesis that major lipid fractions are in-
volved in the etiology of AAA. Consideration should be given
to measures aimed at targeting lipids to reduce risk of AAA,
using established and emerging therapies.
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